Call of Duty fans are quitting Black Ops 6 over the game’s new cel-shaded maps, with some calling it a “horrendous” choice.

AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing a long-acting amylin analogue from Denmark's Gubra in a deal valued at more than $2.2 billion. The ...